Scopio Labs, a medtech innovator transforming cell imaging and diagnostics through AI-powered digital microscopy, has raised $10 million in Series D funding. This strategic round will support the expansion of its advanced full-field imaging platform, enabling faster, more accurate diagnoses in hematology, pathology, and beyond.

Led by CEO Itai Hayut, Scopio Labs is on a mission to modernize diagnostics by replacing outdated analog workflows with AI-assisted digital systems, dramatically improving lab efficiency, accuracy, and accessibility.

---

What Scopio Labs Is Building

Scopio Labs has developed a next-generation digital cell imaging system that combines high-resolution microscopy with advanced AI to analyze entire blood smears and bone marrow aspirates in real time. This innovation enables remote review, full-field visualization, and automated identification of abnormalities - offering clinicians faster decision-making and broader diagnostic reach.

Core products and services include:

• Full-Field Peripheral Blood Smear Review (Scopio X100)
  
• Remote Diagnostic Collaboration and Workflow Integration
  
• Automated Image Analysis Powered by AI and Deep Learning
  
• FDA-Approved Digital Pathology Infrastructure
  

Unlike conventional microscopes, Scopio’s system digitizes and analyzes the entire sample - not just pre-selected snapshots - bringing unprecedented depth and clarity to clinical assessments.

---

Why This Matters Now

Microscopy remains essential to clinical diagnostics, yet most of the world still relies on analog workflows. A 2023 report by MarketsandMarkets estimates that over 70% of global diagnostic labs continue to use manual microscopes, even as sample volumes and staffing pressures increase. Traditional slide review methods are time-consuming, subjective, and bottlenecked by workforce shortages.

Meanwhile, the digital pathology market is projected to grow from $1.2 billion in 2023 to $2.3 billion by 2028, with AI-powered tools and remote collaboration driving adoption. Hematology alone represents a $5.2 billion diagnostics segment globally, with growing demand for automation due to an aging population, chronic disease prevalence, and cancer screening requirements.

Scopio Labs addresses all of these pain points: its full-field platform transforms static slide review into scalable, intelligent, and collaborative diagnostics. Internal deployments report up to 60% faster review times and improved confidence in edge-case diagnoses.

And here’s where the core advantage sharpens. Scopio didn’t try to retrofit AI onto existing infrastructure - it rebuilt the microscope for the age of algorithms. That strategic decision is why its models work more reliably, get faster FDA clearance, and integrate more cleanly into clinical workflows.

This is what many deep-tech founders miss: AI doesn’t create advantage unless you control the context it operates in. Scopio’s real power isn’t just in its machine learning - it’s in how it architected the data pipeline to maximize the model’s signal and minimize noise. The input layer was designed to serve the AI, not the other way around.

---

Founder Insight for Deep-Tech Markets

For startups building in deep-tech or regulated markets, Scopio’s strategy reveals something critical: real transformation doesn’t come from adding AI on top - it comes from re-architecting the foundation.

Scopio didn’t try to bolt AI onto existing microscopes. It built a new imaging paradigm from scratch, one that was designed for machine learning from the ground up. That’s the insight: if your product depends on AI to deliver value, the input infrastructure must be built to feed it - cleanly, completely, and at scale.

Here’s the ultra value: AI works best when you control both the input and the interpretation layers. Founders working in diagnostics, robotics, or industrial AI should take note - owning the full stack isn’t just a technical advantage, it’s the only path to reliability, trust, and FDA-grade performance.

---

Meet the Founder

CEO and co-founder Itai Hayut has led Scopio Labs since its inception, with a background in biomedical engineering and systems innovation. Under his leadership, the company has:

• Secured FDA 510(k) clearance for its hematology platform
  
• Launched clinical deployments across the U.S., Europe, and Asia
  
• Built a full-stack solution encompassing hardware, software, and AI workflows
  

Hayut’s vision is bold: to build a world where digital microscopy is the norm, empowering labs of any size, anywhere, with real-time, AI-enhanced diagnostic clarity.

---

How Scopio Labs Stands Out

Scopio Labs is not the first to attempt digitizing microscopy - but it’s the first to solve for scale and clarity simultaneously, making it a viable enterprise solution for hospitals and labs.

Here’s what sets it apart:

1. Full-Field Imaging: Unlike spot-based digital tools, Scopio captures the entire slide - delivering comprehensive context for diagnostics and avoiding selection bias.
   
2. Remote Diagnostics-Ready: Clinicians can review slides and collaborate in real time across locations, unlocking access in under-resourced or rural regions.
   
3. AI Transparency and Trust: The company’s models are trained and validated on full-field datasets, ensuring explainability, consistency, and clinician trust.
   
4. Workflow Integration: Scopio connects seamlessly into LIS and EMR systems, helping labs transition smoothly from analog to digital without workflow disruption.
   

---

A Market Ready for Disruption

The global digital pathology market is projected to reach $2.3 billion by 2028, driven by rising lab automation needs, clinician shortages, and the scalability of AI. In parallel, the hematology diagnostics segment alone is valued at over $5 billion, and yet over 70% of labs globally still rely on traditional manual microscopy, according to a 2023 Frost & Sullivan report.

Moreover, as remote diagnostics and telepathology surge, the demand for cloud-native, AI-driven microscopy platforms is growing fast - especially in cancer, blood disorders, and infectious disease diagnostics.

Scopio Labs is at the intersection of all three trends: digitization, automation, and decentralization - making it a powerful bet for the future of diagnostics.

---

What’s Next for Scopio Labs

With the new Series D funding, Scopio plans to:

• Expand commercial operations in North America and Europe
  
• Accelerate R&D for additional diagnostic verticals (e.g., oncology, infectious disease)
  
• Pursue global regulatory approvals in Asia-Pacific and Latin America
  
• Invest in cloud-based diagnostic collaboration tools for hospitals and labs
  

Scopio is also building clinical partnerships to deploy its platform in emergency rooms, hematology labs, and national health systems, where diagnostic speed and accuracy directly impact outcomes.